Newborn and Infant Nursing Reviews
Volume 8, Issue 3 , Pages 123-130 , September 2008

In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Evidence for Poor Neonatal Adaptation

  • Wendy Moulsdale, RN, MN

      Affiliations

    • Corresponding Author InformationAddress correspondence to Wendy Moulsdale, RN, MN, Neonatal Intensive Care Unit, Sunnybrook Health Sciences Center, 790 Bay St, Suite 950, Toronto, Ontario, Canada M5G 1N8.
    • ,
  • Susan Hermann, RN, MN(c)

References 

  1. Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Prevalence of depression during pregnancy: systematic review. Obstetrics and Gynecology. 2004;103:698–709
  2. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. Br Med J. 2001;323:257–260
  3. Dietz P, Williams S, Callaghan W, Bachman D, Whitlock E, Hornbrook M. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry. 2007;164:1515–1520
  4. Austin M. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006;36:1663–1670
  5. Way C. Safety of newer antidepressants in pregnancy. Pharmacotherapy. 2007;27:546–552
  6. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49:726–735
  7. Oberlander T, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898–906
  8. Sanz E, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482–487
  9. Oberlander T, Misri S, Fitzgerald C, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230–237
  10. Goldstein DJ, Sundell K. A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Hum Psychopharmacol. 1999;14:319–324
  11. Chambers C, Johnson K, Dick L, Felix R, Lyons Jones K. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015
  12. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Drug Safety. 2005;28:565–581
  13. Chambers C, Hernandez-Diaz S, Van Marter L, et al. Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–587
  14. Levinson-Castiel R, Marlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173–176
  15. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720–726
  16. Zeskind P, Stephens L. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368–375
  17. Alwan S, Reefhuis J, Rasmussen S, Olney R, Friedman J. Use of selective serotonin reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684–2692
  18. Davis R, Rubanowice D, McPhillips H, Raebel , et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16:1086–1094
  19. Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609–610
  20. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiologic studies. Psychol Med. 2000;30:89–94
  21. American Academy of Pediatrics , Committee on Drugs . Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105:880–887
  22. Health Canada . Health Canada advises of potential adverse effects of SSRIs and other antidepressants on newborns. Retrieved electronically November 3, 2007 from http://www.hc.gc.ca/english/protection/warnings/2004/2004_44.htm2004;
  23. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates. Can Med Assoc J. 2005;172:1457–1459
  24. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;5:255–261
  25. Cohen L, Altshuler L, Harlow B, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499–507
  26. Zajecka J, Tracy K, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58:290–298
  27. Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psych Pract. 2005;11:177–191
  28. Moses-Kolko E, Bogen D, Perel J, Bregar A, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2373–2383
  29. Lattimore K, Donn S, Kaciroti N, Kemper A, Neal C, Vazquez D. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25:595–604
  30. Hess DR. Retrospective studies and chart reviews. Respir Care. 2004;49:1171–1174
  31. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129–1132
  32. Hegerl U, Bottlender R, Gallinat J, Kuss H, Ackenheil M, Moller H. The serotonin syndrome scale: first results of validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96–103
  33. Greene C, Goodman M. Neonatal abstinence syndrome: strategies for care of the drug-exposed infant. Neonatal Netw. 2003;22:15–24
  34. Brazelton TB. The Brazelton Neonatal Behavioral Assessment Scale: Introduction. Monographs of the Society for Research in Child Development. 1978;43:1–13
  35. Finnegan LP. Neonatal abstinence syndrome: Assessment and pharmacotherapy. In:  Nelson N editors. Current therapy in neonatal medicine-2nd ed. Ontario: BC Decker; 1990;
  36. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 2008;115:283–289
  37. Kallen B. Neonatal characteristi after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312–316
  38. The US Food and Drug Administration . Selective serotonin reuptake inhibitors: Increased risk of neonatal persistent pulmonary hypertension. Available at: http:www.fda.gov/cder/drug/InfoSheets/HCP/paroxetineHCP.htm2006;
  39. Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch Pediatr Adolesc Med. 2004;158:307–308
  40. Nordeng H, Lindemann R, Perminov K, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatrica. 2001;90:288–291
  41. Beal JA. Evidence for best practices in the neonatal period. Am J Matern Child Nursing. 2005;30:397–403
  42. American Academy of Pediatrics . Neonatal drug withdrawal. Pediatrics. 1998;101:1079–1088
  43. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18–27
  44. Keltner N, Hall S. Neonatal serotonin syndrome. Perspectives in Psychiatric Care. 2005;41:88–91
  45. Haddad P, Pal B, Clarke P, Wieck A, Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome?. Journal of Psychopharmacology. 2005;19:554–557
  46. Maciag D, Simpson K, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology. 2006;31:47–57
  47. Wen S, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology. 2006;194:961–966

PII: S1527-3369(08)00080-9

doi: 10.1053/j.nainr.2008.06.006

Newborn and Infant Nursing Reviews
Volume 8, Issue 3 , Pages 123-130 , September 2008

Article Tools